MedTrace Logo

Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD)

NCT01380717 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2014-02-27

No results posted yet for this study

Summary

Patients with reduced kidney function have a higher risk of heart disease and death. Studies have shown that blood vessels in patients with hypertension change with a decrease of lumen size and growth of the vessel wall. By treating patients with antihypertensive certain medication vessel lumen and walls normalize. Treating hypertension in patients with chronic kidney disease slows the progression of kidney function loss.

The aim is to compare different degrees of antihypertensive medication in patients with chronic kidney disease and hypertension will slow the progression of kidney loss.

Conditions

Interventions

DRUG

Beta-blocker, ACE-inhibitor

Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day

DRUG

Calcium Channel Blockers, ACE-Inhibitor

Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Niels Henrik Buus, DrMedSc · Department og Renal Medicine, Aarhus University Hospital, Skejby

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01380717 on ClinicalTrials.gov